Discoid Lupus Erythematosus

Back

Background

Cutaneous lupus erythematosus (CLE) can be divided into three main subtypes: acute, subacute, and chronic, all of which demonstrate photosensitivity.

Acute cutaneous lupus erythematosus (ACLE) most commonly presents as symmetric erythema overlying the malar cheeks and nasal bridge with sparing of the nasolabial folds (butterfly rash). However, it can also present as a diffuse morbilliform eruption with erythema and edema of the hands, with prominent sparing of the joints.

Subacute cutaneous lupus erythematosus (SCLE) characteristically presents as annular or psoriasiform plaques in a photodistribution.

Chronic cutaneous lupus erythematosus (CCLE) can be further divided into three main types: discoid lupus erythematosus (DLE), tumid lupus, and lupus panniculitis. Tumid lupus typically presents with juicy papules and plaques that lack scale and heal without scarring, whereas lupus panniculitis involves the subcutaneous tissue, leading to painful subcutaneous nodules that heal with depression and atrophy.

DLE classically presents with erythematous-to-violaceous, scaly plaques with prominent follicular plugging that often results in scarring and atrophy (see the images below). DLE may occur in the absence of systemic disease, or it may occur in association with systemic lupus erythematosus (SLE). DLE is the most common subtype of CLE.[1]



View Image

Discoid lupus erythematosus on the face.



View Image

Chronic scarred lesion of discoid lupus erythematosus.

The risk of progression to SLE in patients with DLE has been demonstrated to be higher than previously reported. The reported rates were 16.7% progression to SLE within 3 years of diagnosis in one international study and 17% progression within a mean time of 8 years in a second study,[2, 3] as compared with previous data indicating that less than 5-10% of patients with DLE progress to SLE.[4]

A review showed an SLE progression rate of 26% in pediatric patients with DLE.[5] Another review reported that SLE developed in 12% of children with DLE. Onset of symptoms before or at the age of 10 years predicted progression to SLE.[6]  

The reported interval from DLE diagnosis to SLE onset has varied widely, with a mean time to progression of approximately 8 years in one study, with another small cohort study reporting the median time to progression from DLE to SLE of 453 days.[7] Overall, patients with DLE rarely fulfill 4 or more of the 17 Systemic Lupus International Collaborating Clinics (SLICC) criteria used to classify SLE.[8] Serologic abnormalities are uncommon.

Therapy with photoprotection, topical corticosteroids, and antimalarial agents is often effective. However, immunosuppressive and/or immunomodulatory agents may be required for recalcitrant disease (see Treatment and Medication).

Etiology

Lupus erythematosus is a polygenic autoimmune disease linked to various HLA subtypes, immune signaling, and environmental factors, which ultimately leads to autoantibody production and T-cell dysfunction. Although the exact etiology of discoid lupus erythematosus (DLE) is not well understood, genetic polymorphisms, mutations, and risk alleles have been identified in different populations of CLE patients, with most of them associated with innate and adaptive immunity pathways. Genes that act in apoptosis, leukocyte migration, type I interferon (IFN) pathway, complement cascade, antigen presentation, and antibody production are among the most frequently affected, including ITGAM, which has been found to portend high risk for DLE. It has also been determined that immunoglobulins play a role in the development of CLE, with immunoglobulin G (IgG), specifically, being responsible for the majority of immune complexes in DLE.

DLE likely occurs in genetically predisposed individuals, but the exact genetic connection has not been determined. In CLE, ultraviolet (UV) light exposure and/or stress are thought to trigger a cascade activating self-reactive B and T lymphocytes, which ultimately activates the innate and adaptive immune system and leads to tissue inflammation.[9]

Emerging research has shown a role for interferons, particularly IFN-1, and JAK-STAT (Janus kinase/signal transducers and activators of transcription) signaling in DLE, postulating the potential for treatment with JAK inhibitors.[10] Additionally, fibrosis in DLE has been linked to transforming growth factor (TGF)–β signaling, providing another molecular target for therapy.[11] The overexpression of two microRNAs (miR-31 and miR-485-p) has also been reported to contribute to DLE pathogenesis.[12]

Epidemiology

Worldwide, the prevalence of systemic lupus erythematosus (SLE) ranges from 17-48 cases per 100,000 population. The highest prevalence of SLE occurs in persons aged 40-60 years, with SLE onset most often occurring in patients in their 20s and 30s. SLE is approximately 8 times more common in women than in men.[13]

In Europe and the United States, the incidence of isolated cutaneous lupus erythematosus (CLE) has ranged from 4 to 4.3 cases per 100,000 population, slightly higher than the incidence of SLE (approximately 3 cases per 100,000 population).[2, 13, 14] In an epidemiological study from Olmstead County, Minnesota, Jarukitsopa et al demonstrated that the incidence of CLE rises steadily with age, peaking at age 60-69 years.[14]

Discoid lupus erythematosus (DLE) is responsible for 50-85% of cases of CLE and occurs 2-3 times more frequently in women than in men. DLE has also been reported to have a higher incidence in African Americans than in Whites. Although DLE may occur at any age, it most often develops in persons aged 20-40 years.

A limited number of population-based studies have estimated the incidence of DLE in the absence of SLE (“primary” DLE).[15, 16] In an epidemiological study using the Georgia Lupus Registry, Drenkard et al reported an overall age-adjusted DLE incidence of 3.7 cases per 100,000 person-years among Georgia residents.[15]

Prognosis

Although the prognosis of patients with discoid lupus erythematosus (DLE) is favorable regarding mortality, morbidity can be considerable. Patients may experience pain or burning of their lesions, or occasionally pruritus. Many patients with DLE experience disfigurement from the scars or atrophy that can develop. Scarring alopecia is particularly disturbing for patients. Prompt treatment of early lesions may help prevent or lessen the severity of scarring and atrophy.

DLE can negatively impact patient quality of life.[17] In fact, a study demonstrated that over one third of patients with cutaneous lupus met criteria for depression or anxiety with need for psychiatric intervention.[18] Furthermore, a significant correlation has been found between skin disease activity in cutaneous lupus and quality of life.[19]

Exacerbation is common with increased sun exposure, particularly in the spring and summer. Serious systemic disease is rare, but when it occurs, patients may develop life-altering sequelae. Malignant degeneration within DLE lesions is uncommon, but may occur. Hence, prompt biopsy of suggestive lesions developing within chronic DLE lesions is warranted.[20, 21]

Patient Education

Instruct patients in sun-avoidance techniques and the proper use of sunscreens, wide-brimmed hats, and protective clothing. Advise patients to quit smoking. Discuss the possibility of systemic involvement with patients.

History

Patients may report mild pruritus or occasional pain or burning within the lesions, but most patients are asymptomatic. According to one study, approximately 16% of patients with discoid lupus erythematosus (DLE) may develop systemic involvement within 3 years of diagnosis.[2] Another cohort study reported that 17% of patients with cutaneous lupus erythematosus (CLE) met criteria for systemic lupus erythematosus (SLE) within a mean time of 8 years.[3] Of note, systemic disease was generally mild in these patients, and the diagnosis of SLE was most commonly established by meeting mucocutaneous and laboratory criteria.

Patients may manifest any sign or symptom of SLE; therefore, the history should include an assessment for serologic and/or hematologic abnormalities, arthralgia or arthritis, pleuritis, pericarditis, neurologic involvement, and renal involvement. A study demonstrated increased risk of photosensitivity, leukopenia, anti-Smith antibody, and decreased risk of arthritis and pleuritis in patients with SLE and DLE.[22] There was no significant association between DLE and anti-ds DNA antibodies, nephritis, or end-stage renal disease.

Malignant degeneration of chronic lesions of DLE leading to nonmelanoma skin cancer is rare. The incidence of squamous cell carcinoma arising in DLE lesions ranges from 2.3-3.3%.[20] Dark-skinned individuals may be more prone to skin cancer because of the lack of pigmentation within the chronic lesion, combined with chronic inflammation and continued sun damage. Reported risk factors for the development of squamous cell carcinoma within lesions of chronic DLE include male sex, early age of onset, refractory disease, lip involvement, and tobacco use.[20]

Porphyria cutanea tarda (PCT) appears to be overrepresented in patients with CLE. Often, PCT is discovered when antimalarials are first administered. Lichen planus–like lesions may be due to an overlap between CLE and lichen planus or may occur as a result of antimalarial therapy.

Physical Examination

Discoid lupus erythematosus (DLE) lesions frequently are characteristic. The primary lesion is an erythematous papule or plaque with slight-to-moderate scale (see the images below). As the lesion progresses, the scale may thicken and become adherent. Pigmentary changes may develop, with hypopigmentation in the central, or inactive area, and hyperpigmentation at the active border.



View Image

Discoid lupus erythematosus on the face.



View Image

Chronic scarred lesion of discoid lupus erythematosus.

Lesions spread centrifugally and may merge. As lesions age, dilation of follicular openings occurs with a keratinous plug, termed follicular plugging or patulous follicles (see the image below). Resolution of the active lesion results in atrophy and scarring.



View Image

Lesions of discoid lupus erythematosus in the conchal bowl demonstrate patulous follicles with follicular plugging.

At any time, individual lesions may have any or all of these features. Early lesions may be difficult to distinguish from those of subacute cutaneous lupus erythematosus (SCLE). Facial lesions may be misdiagnosed as actinic keratoses or squamous cell carcinomas. DLE lesions are often photodistributed, but relatively unexposed skin may also be affected. The conchal bowls and scalp are both common areas of involvement. Permanent scarring alopecia may result (see images below).



View Image

Scarring alopecia of discoid lupus erythematosus.



View Image

Widespread scarring alopecia.

Patients with DLE often are divided into two subsets: localized and widespread (disseminated). Localized DLE occurs when the head and neck only are affected, while widespread DLE occurs when other areas are affected, regardless of whether disease of the head and neck is seen. Patients with widespread involvement often have hematologic and serologic abnormalities, are more likely to develop systemic lupus erythematosus (SLE), and are more difficult to treat.

Mucosal surfaces may also be affected by lesions that appear identical to DLE of the skin. Palms and soles may be affected by DLE, but this occurs in less than 2% of patients (see the image below).[23]



View Image

Palmar lesions of discoid lupus erythematosus.

DLE lesions may become hypertrophic or verrucous (see the image below). This subset is manifested by wartlike lesions, most often on the extensor arms. Hypertrophic lesions of chronic lupus erythematosus must be differentiated from warts, keratoacanthomas, or squamous cell carcinoma. These lesions are challenging to treat.[24]

Lupus panniculitis, a form of CCLE that manifests with tender, inflammatory nodules in the early phase, results in eventual destruction of the subcutaneous fat with resulting atrophy and contour change. Lupus panniculitis may be accompanied by overlying typical DLE lesions and/or may occur in patients with SLE.[25]



View Image

Hypertrophic lesions of chronic cutaneous lupus erythematosus on the dorsal hands. Characteristic lesions were observed elsewhere.

Classification Criteria

Development of classification criteria specific for the diagnosis of DLE was initiated by experts using a Delphi method in 2017.[26] While validation of these criteria is required, they provide a preliminary diagnostic classification scheme to be used clinically and for research. The 12 characteristics, stratified by category, include the following:

Morphology is as follows:

Histopathology is as follows:

Location is as follows:

Approach Considerations

Screening for systemic lupus erythematosus (SLE) should occur upon diagnosis of discoid lupus erythematosus (DLE). This should consist of a thorough history and physical examination, as well as standard laboratory screening including complete blood cell count, renal function tests, and urinalysis. Hematologic and serologic abnormalities may be present and an elevated sedimentation rate may occur in some patients. Additionally, rheumatoid factor may be positive and complement levels may be decreased. Abnormal renal function tests and/or urinalysis with proteinuria may reflect the presence of renal involvement.

Some patients with DLE (approximately 20%) manifest a positive antinuclear antibody (ANA) when tested with human substrates. HEp-2 cells currently are the most common substrate used in commercial laboratories.

Anti-Ro (SS-A) autoantibodies are present in up to 20% of patients. Antinative deoxyribonucleic acid (DNA, either double-stranded or nDNA) or anti-Sm antibodies usually reflect SLE, and they may occur in some patients (5-20%).[27] In one study, levels of ANA, anti-RNP, anti-dsDNA, and anti-ssDNA IgG were associated with disease activity of DLE as determined by the Cutaneous Lupus Disease Area and Severity Index (CLASI).[28]

Other Tests

Deposition of immunoglobulin and/or complement at the dermoepidermal junction is a characteristic feature of lupus erythematosus. Tissue may be examined from skin lesions (lesional) or normal skin (nonlesional). Nonlesional biopsies may be from photoexposed or nonexposed surfaces. Testing of nonlesional, nonexposed skin is termed the lupus band test (LBT).

The use and interpretation of these tests vary according to the biopsy site. Approximately 90% of patients with discoid lupus erythematosus (DLE) manifest a positive direct immunofluorescence (DIF) test on lesional skin; however, the presence of immunoreactants in the basement membrane zone of lesional skin is not specific for lupus and can be seen in a variety of inflammatory skin diseases. Older lesions or very early lesions may be more likely to be negative on immunofluorescence microscopy. Most commonly, DLE may be diagnosed by clinical examination and histopathologic findings, rather than relying on DIF testing.

Only patients with systemic lupus erythematosus (SLE) have a positive LBT, defined as the presence of multiple immunoreactants in the basement membrane zone. The LBT is neither sensitive nor specific and has mostly been replaced by advances in serologic testing.

Histologic Findings

The characteristic histopathologic alterations observed in discoid lupus erythematosus (DLE) include the following:

Often, an abundance of mucin is seen within the dermis. The histopathologic features differ depending on the type and age of the lesion.

Approach Considerations

The goals of management of discoid lupus erythematosus (DLE) are to halt disease activity, thereby preventing scarring, and to prevent the development of further lesions. Advise patients that the development of serious systemic disease is possible, although rare. Regular repeated clinical evaluation with a thorough review of systems accompanied by simple laboratory studies (complete blood cell count, renal function, urinalysis) is usually sufficient to monitor for progression from primary cutaneous disease to systemic involvement.

Therapy begins with the use of sun-protective measures, including sunscreens, photoprotective clothing, wide-brimmed hats, and behavior alteration. Cosmetic measures, such as cover-up makeup or wigs, may be suggested for appropriately selected patients. Makeup used for camouflage includes Covermark and Dermablend.

Standard medical therapy includes topical or intralesional corticosteroids and antimalarials.[1, 29] Topical calcineurin inhibitors have also been used in patients with cutaneous lupus erythematosus (CLE). In addition, topical retinoids have been reported to be helpful. Topical imiquimod was reported to be effective in one patient. Systemic corticosteroids are typically avoided, given that the dose and duration of therapy needed to maintain control of cutaneous disease often results in substantial steroid-related adverse effects. Therefore, for recalcitrant disease, immunosuppressants and immunomodulators, including methotrexate, mycophenolate mofetil, and thalidomide, amongst others, should be considered.

Activity

Since chronic CLE is exacerbated by sunlight and other UV exposure, advise patients to take precautions by limiting exposure to sunlight to the early morning or late afternoon, when the sun is less intense. Even during these times, strict photoprotective measures should be practiced. Advise patients to avoid artificial light sources, such as tanning beds.

Consultations

Consultation with the following specialists may be helpful:

Antimalarial Therapy

Antimalarial therapy seems to lessen the progression to systemic lupus erythematosus (SLE) and to lower the risk of thrombovascular disease.[30, 31] Alternative therapies include immunosuppressive agents,[32, 33] thalidomide or lenalidomide,[34, 35, 36]  and oral or topical retinoids. These agents are typically used in antimalarial-resistant patients. In most patients, the antimalarial should be continued during treatment with other agents, unless a complication due to the antimalarial occurs. The rationale for continuing the antimalarial therapy includes its ability to reduce the risk of disease progression to SLE as well as its photoprotective benefits.

Hydroxychloroquine is the first-line systemic agent for discoid lupus erythematosus (DLE), whereas chloroquine is considered second-line antimalarial therapy in the United States.[37] Both hydroxychloroquine and chloroquine are associated with an increased risk of retinal toxicity and should not be used in combination.[38]

Quinacrine has also been used for recalcitrant cutaneous lupus erythematosus (CLE) as combination therapy with either hydroxychloroquine or chloroquine.[39] A retrospective cohort study demonstrated that the combination of quinacrine with other antimalarials does not increase the risk for ocular toxicity compared with monotherapy with hydroxychloroquine or chloroquine.[40]  Quinacrine is not associated with retinal toxicity and can be considered in patients who are at risk for or who have experienced antimalarial-induced retinopathy. Quinacrine down-regulates responses of toll-like receptor (TLR)–3, TLR-4, and TLR-8.[41]

Of note, quinacrine is not commercially available in the United States and is available only from compounding pharmacies. It is not currently approved for human use in the United States.

Traditionally, antimalarials have been considered less effective in patients who smoke; however, it is also possible that DLE is worse in these patients. A study demonstrated that cigarette smoking did not have a significant impact on response to hydroxychloroquine in patients with DLE. Rather, disseminated DLE and the presence of concomitant SLE were both significantly associated with decreased therapeutic efficacy.[42] However, a meta-analysis concluded that patients with CLE who smoke have a 2-fold decreased chance of cutaneous improvement with antimalarial therapies.[43]

Efforts regarding smoking cessation are advisable in patients with DLE who smoke or who are exposed to secondary smoke.[44] Furthermore, a study demonstrated that patients with CLE who smoked had more severe cutaneous disease, had inferior quality of life, and were more frequently treated with a combination of hydroxychloroquine and quinacrine than were nonsmokers.[45]

Ocular toxicity is a well-known risk of both hydroxychloroquine and chloroquine, as they can deposit in the retina with subsequent irreversible retinopathy. Thus, these two medications should not be used in combination. The American Academy of Ophthalmology 2016 guidelines recommend a baseline fundus examination with subsequent annual screening after 5 years of treatment.[38] High dose and long duration of treatment are the most significant risk factors for retinopathy. The risk of toxicity at the recommended dose up to 5 years is under 1%, and up to 10 years is 2%. After 20 years of treatment, however, risk of toxicity rises to almost 20%. Despite these guidelines, in clinical practice, ocular examinations are still typically recommended at baseline (within 3 months of initiating the antimalarial agent) and annually thereafter.

A large single-center cohort study demonstrated a reasonable safety profile for antimalarials in the treatment of lupus, with less than 20% of patients presenting with at least one adverse effect during treatment.[46] While most common adverse effects were mild-to-moderate cutaneous and gastrointestinal manifestations, ocular alterations were the most common cause for treatment discontinuation.

Corticosteroid and Immunomodulator Therapy

Topical corticosteroids are selected for the type of lesion under treatment and for the site of involvement. For example, solutions, lotions, oil, or foams are preferred for the scalp, weaker agents are used on the face, and superpotent agents are used under occlusion for hypertrophic lesions. Topical calcineurin inhibitors may also be used, most often for facial lesions when the patient is taking appropriate breaks from topical corticosteroids.

Intralesional injection of corticosteroids (typically, the authors use triamcinolone acetonide 3 mg/mL) is useful as adjunctive therapy for individual lesions. Potential for atrophy relates to the amount of corticosteroid injected in any one area; therefore, dilute concentrations and low volumes are preferred. In addition, the treating physician must take care to limit the total dose of the injections at any given clinic visit to avoid systemic toxicity from the steroids; for example, if a patient is given 10 mL of triamcinolone 3 mg/mL, this means that the patient has received a total of 30 mg, and toxicity is similar as if it had been delivered orally or by intramuscular injection.

Among immunosuppressives, methotrexate, mycophenolate mofetil, and azathioprine, amongst others, may be considered.[32, 33] Two reports have documented the value of mycophenolate mofetil for treatment of cutaneous lesions of lupus erythematosus, including one study that used mycophenolate mofetil in antimalarial-resistant subjects.[47, 48]

Multiple other agents have case reports, case series, or early clinical trials to support their use in cutaneous lupus erythematosus (CLE), including lenalidomide,[49, 50] tofacitinib,[10, 51] apremilast,[52] intravenous immunoglobulin,[53] belimumab,[54, 55]  sirolimus,[56]  and anifrolumab.[57, 58, 59, 60, 61, 62, 63]

In the authors’ experience, systemic corticosteroids are rarely effective and frequently lead to steroid-related adverse effects at the doses needed to manage cutaneous disease.

Excision and Laser Therapy

Excision of burned-out, scarred lesions is possible; however, reactivation of inactive lesions has been reported in some patients.

Laser therapy may be useful for lesions with prominent telangiectasias; however, one must consider the risk of reactivation with this form of therapy. An open trial in a small group of patients has demonstrated the efficacy of pulsed-dye laser (PDL) therapy for discoid lupus erythematosus (DLE) lesions. Another randomized controlled trial involving 48 lesions in 9 DLE patients failed to demonstrate a significant difference in modified CLASI scores with PDL compared with a control group.[64] Before using this therapy in patients, at a minimum, a test area should be treated to make certain that the DLE does not flare.[65]

Long-Term Monitoring

Follow up patients with discoid lupus erythematosus (DLE) at regular intervals. Response to therapy varies from several weeks to several months. At each visit, question the patient about new symptoms that may reflect systemic disease. At regular intervals, perhaps annually in otherwise asymptomatic patients, perform routine laboratory studies for assessment, including complete blood cell count, renal function tests, and urinalysis. Repeat antibody testing is needed only if a change in symptomatology is noted.

Guidelines Summary

The following organizations have released guidelines for the management of discoid lupus erythematosus. Key diagnostic and treatment recommendations have been reviewed and integrated throughout the article.

Medication Summary

Hydroxychloroquine and chloroquine phosphate have shown beneficial effects in treating discoid lupus erythematosus (DLE). Additionally, the antimalarial drugs may prevent the development of systemic lupus erythematosus (SLE) in patients with DLE, and they might decrease the risk of cardiovascular disease.[30] Alternative therapies, anecdotal reports, and small open-label trials (as reported by Callen[66] ) suggest that the following agents may be useful in some patients:

Hydroxychloroquine sulfate (Plaquenil)

Clinical Context:  Hydroxychloroquine is used for the treatment of DLE and SLE. It inhibits chemotaxis of eosinophils and locomotion of neutrophils and impairs complement-dependent antigen-antibody reactions. Hydroxychloroquine sulfate 200 mg is equivalent to 155 mg hydroxychloroquine base and 250 mg chloroquine phosphate.

Chloroquine (Aralen, Chloroquine phosphate)

Clinical Context:  Chloroquine inhibits chemotaxis of eosinophils and locomotion of neutrophils and impairs complement-dependent antigen-antibody reactions.

Class Summary

Antimalarial agents may have immunomodulatory properties. Hydroxychloroquine is the drug of choice when a systemic agent is needed for discoid lupus erythematosus (DLE). Chloroquine is second-line antimalarial therapy. Chloroquine and hydroxychloroquine should not be used in combination due to the increased risk of ocular toxicity. The antimalarial drugs may prevent the development of systemic lupus erythematosus (SLE) in patients with DLE, and they might decrease the risk of cardiovascular disease.

Triamcinolone acetonide (Kenalog-10, Kenalog-40)

Clinical Context:  Triamcinolone can be administered intralesionally in a concentration of 3-5 mg/mL. The amounts injected should be recorded. Systemic adverse effects are uncommon with low doses. Atrophy is possible and is dose dependent.

Class Summary

Corticosteroids are anti-inflammatory agents that suppress the immune system at several levels, including through the inhibition of inflammatory cells and the production of antibodies.

Dapsone

Clinical Context:  Dapsone's mechanism of action is similar to that of sulfonamides, in which competitive antagonists of para-aminobenzoic acid (PABA) prevent the formation of folic acid, inhibiting bacterial growth. The anti-inflammatory action may relate to suppression of neutrophil function by inhibition of the halide-myeloperoxidase system.

Class Summary

Leprostatic agents may modulate the immune system.

Auranofin (Ridaura)

Clinical Context:  Gold is taken up by macrophages, which, in turn, inhibit phagocytosis and lysosomal membrane stabilization. Gold alters immunoglobulins, decreasing prostaglandin synthesis and lysosomal enzyme activity.

Class Summary

Gold compounds have proven effective in the treatment of inflammation with autoimmune etiology.

Methotrexate (Jylamvo, Otrexup, Rasuvo)

Clinical Context:  Methotrexate reversibly inhibits dihydrofolate reductase; it limits the availability of 1-carbon fragments necessary for the synthesis of purines and the conversion of deoxyuridylate to thymidylate in the synthesis of DNA and cell reproduction. Methotrexate is extensively used to treat cancer, rheumatoid arthritis, and psoriasis and is used as a steroid-sparing agent in various autoimmune conditions.

Thalidomide (Thalomid)

Clinical Context:  Thalidomide is an immunomodulatory agent that may suppress excessive production of tumor necrosis factor (TNF)-alpha and may down-regulate selected cell-surface adhesion molecules involved in leukocyte migration. If the patient weighs less than 50 kg (110 lb), start the individual at the low end of the dose regimen.

Azathioprine (Azasan, Imuran)

Clinical Context:  Azathioprine antagonizes purine metabolism and inhibits the synthesis of DNA, ribonucleic acid (RNA), and proteins. It may decrease the proliferation of immune cells, which results in lower autoimmune activity.

Mycophenolate (CellCept, MMF, Myfortic)

Clinical Context:  Mycophenolate inhibits inosine monophosphate dehydrogenase and suppresses de novo purine synthesis by lymphocytes, thereby inhibiting their proliferation. It inhibits antibody production.

Class Summary

Immunomodulators affect factors that regulate the immune system.

Anifrolumab (Anifrolumab-fnia, Saphnelo)

Clinical Context:  Anifrolumab, a human monoclonal antibody targeting type 1 interferon receptor subunit 1, was approved by the US Food and Drug Administration (FDA) in 2021 for adults with moderate-to-severe systemic lupus erythematosus (SLE). In the phase 3 trials for anifrolumab in SLE, this medication also demonstrated benefit in lupus-associated skin disease, with 49% of patients in the anifrolumab group having a 50% or more reduction in CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index) activity score versus 25% in the placebo group.

Since then, several case reports and series have demonstrated substantial improvement in cutaneous and mucosal disease in adult and adolescent patients with DLE. Notably, this treatment option has a favorable side-effect profile, with upper respiratory tract infections, nasopharyngitis, infusion-related reactions, bronchitis, and herpes zoster as the most common adverse effects noted in the original phase 3 trials of anifrolumab in patients with SLE. Given the risk of zoster, experts recommend one dose of Shingrix (zoster vaccine recombinant) prior to initiation of anifrolumab, followed by the second dose as per the typical schedule of this series.

Acitretin (Soriatane (DSC))

Clinical Context:  Acitretin is a retinoic acid analog similar to etretinate and isotretinoin. Etretinate is the main metabolite, and acitretin has demonstrated clinical effects close to those seen with etretinate. The mechanism of action is unknown.

Isotretinoin (Absorica, Absorica LD, Amnesteem)

Clinical Context:  Isotretinoin is a synthetic 13-cis isomer of naturally occurring tretinoin (trans -retinoic acid). Both agents are structurally related to vitamin A. Isotretinoin decreases sebaceous gland size and sebum production. It may inhibit sebaceous gland differentiation and abnormal keratinization.

A US Food and Drug Administration (FDA)–mandated registry is now in place for all individuals prescribing, dispensing, or taking isotretinoin. For more information on this registry, see iPLEDGE. This registry aims to decrease the risk of pregnancy and unwanted and potentially dangerous adverse effects during a course of isotretinoin therapy.

Class Summary

Retinoids have the ability to regulate cell proliferation and the immune system.

How is cutaneous lupus erythematosus (CLE) categorized?What are the signs and symptoms of discoid lupus erythematosus (DLE)?What is the risk of progression to systemic lupus erythematosus (SLE) in patients with discoid lupus erythematosus (DLE)?How is discoid lupus erythematosus (DLE) treated?What causes discoid lupus erythematosus (DLE)?What is the prevalence of discoid lupus erythematosus (DLE)?What is the prognosis of discoid lupus erythematosus (DLE)?What is included in patient education about discoid lupus erythematosus (DLE)?Which clinical history findings are characteristic of discoid lupus erythematosus (DLE)?Which physical findings are characteristic of discoid lupus erythematosus (DLE)?How is discoid lupus erythematosus (DLE) differentiated from other variants of chronic cutaneous lupus erythematosus (CCLE)?What are the classification criteria for the diagnosis of discoid lupus erythematosus (DLE)?Which conditions should be included in the differential diagnoses of discoid lupus erythematosus (DLE)?What are the differential diagnoses for Discoid Lupus Erythematosus?What is the role of lab testing in the workup of discoid lupus erythematosus (DLE)?What is the role of biopsy in the evaluation of discoid lupus erythematosus (DLE)?Which histologic findings are characteristic of discoid lupus erythematosus (DLE)?How is discoid lupus erythematosus (DLE) treated?Which activity modifications are used in the treatment of discoid lupus erythematosus (DLE)?Which specialist consultations are beneficial to patients with discoid lupus erythematosus (DLE)?What is the role of antimalarial therapy in the treatment of discoid lupus erythematosus (DLE)?Which antimalarial agents are used in the treatment of discoid lupus erythematosus (DLE)?What is the efficacy of antimalarial agents in the treatment of discoid lupus erythematosus (DLE)?What are the adverse effects of antimalarials for the treatment of discoid lupus erythematosus (DLE)?What is the role of corticosteroid therapy in the treatment of discoid lupus erythematosus (DLE)?What is the role of immunomodulator therapy in the treatment of discoid lupus erythematosus (DLE)?What is the efficacy of corticosteroid therapy for the treatment of discoid lupus erythematosus (DLE)?What is the role of excision in the treatment of discoid lupus erythematosus (DLE)?What is the role of laser therapy in the treatment of discoid lupus erythematosus (DLE)?What is included in the long-term monitoring of patients with discoid lupus erythematosus (DLE)?Which medications are used in the treatment of discoid lupus erythematosus (DLE)?Which medications in the drug class Interferon Antagonists are used in the treatment of Discoid Lupus Erythematosus?Which medications in the drug class Immunomodulators are used in the treatment of Discoid Lupus Erythematosus?Which medications in the drug class Gold compounds are used in the treatment of Discoid Lupus Erythematosus?Which medications in the drug class Leprostatic agents are used in the treatment of Discoid Lupus Erythematosus?Which medications in the drug class Corticosteroids are used in the treatment of Discoid Lupus Erythematosus?Which medications in the drug class Antimalarial agents are used in the treatment of Discoid Lupus Erythematosus?

Author

Ellen E Anshelevich, Doctorate of Medicine Candidate, Hackensack Meridian School of Medicine, Research Trainee, Brigham and Women's Hospital

Disclosure: Nothing to disclose.

Coauthor(s)

Jeffrey P Callen, MD, Professor of Medicine (Dermatology), Chief, Division of Dermatology, University of Louisville School of Medicine

Disclosure: Received income in an amount equal to or greater than $250 from: Biogen US (Adjudicator for study entry cutaneous lupus erythematosus); Priovant (Adjudicator for entry into a dermatomyositis study); IQVIA (Serono - adjudicator for a study of cutaneous LE) <br/>Received honoraria from UpToDate for author/editor; Received royalty from Elsevier for book author/editor; Received dividends from trust accounts, but I do not control these accounts, and have directed our managers to divest pharmaceutical stocks as is fiscally prudent from Stock holdings in various trust accounts include some pharmaceutical companies and device makers for these trust accounts for: Stocks held in various trust accounts: Allergen; Amgen; Pfizer; 3M; Johnson and Johnson; Merck; Abbott Laboratories; AbbVie; Procter and Gamble;; Celgene; Gilead; CVS; Walgreens; Bristol-Myers Squibb.

Ruth Ann Vleugels, MD, MPH, Assistant Professor of Dermatology, Harvard Medical School; Associate Physician, Department of Dermatology, Brigham and Women's Hospital; Associate Physician, Department of Immunology and Allergy, Children's Hospital Boston

Disclosure: Nothing to disclose.

Specialty Editors

Julia R Nunley, MD, Professor, Department of Dermatology, Virginia Commonwealth University Medical Center

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: American Board of Dermatology<br/>Author for: Up-to-date.

Chief Editor

William D James, MD, Emeritus Professor, Department of Dermatology, University of Pennsylvania School of Medicine

Disclosure: Received income in an amount equal to or greater than $250 from: Elsevier<br/>Served as a speaker for various universities, dermatology societies, and dermatology departments.

Additional Contributors

A Brooke W Eastham, MD, Board Certified Dermatologist, Nashville Skin and Cancer

Disclosure: Nothing to disclose.

Craig A Elmets, MD, Professor and Chair, Department of Dermatology, Director, Chemoprevention Program Director, Comprehensive Cancer Center, UAB Skin Diseases Research Center, University of Alabama at Birmingham School of Medicine

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: University of Alabama at Birmingham; University of Alabama Health Services Foundation<br/>Serve(d) as a speaker or a member of a speakers bureau for: Ferndale Laboratories<br/>Received research grant from: NIH, Veterans Administration, California Grape Assn<br/>Received consulting fee from Astellas for review panel membership; Received salary from Massachusetts Medical Society for employment; Received salary from UpToDate for employment. for: Astellas.

Elizabeth Tkachenko, University of Massachusetts Medical School

Disclosure: Nothing to disclose.

Sheena Desai, MD Candidate, Tufts University School of Medicine; MBA Candidate, Brandeis University, The Heller School for Social Policy and Management

Disclosure: Nothing to disclose.

References

  1. [Guideline] O'Kane D, McCourt C, Meggitt S, et al. British Association of Dermatologists guidelines for the management of people with cutaneous lupus erythematosus 2021. Br J Dermatol. 2021 Dec. 185 (6):1112-23. [View Abstract]
  2. Grönhagen CM, Fored CM, Granath F, Nyberg F. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden. Br J Dermatol. 2011 Jun. 164(6):1335-41. [View Abstract]
  3. Wieczorek IT, Propert KJ, Okawa J, Werth VP. Systemic symptoms in the progression of cutaneous to systemic lupus erythematosus. JAMA Dermatol. 2014 Mar. 150 (3):291-6. [View Abstract]
  4. Prystowsky SD, Gilliam JN. Discoid lupus erythematosus as part of a larger disease spectrum. Correlation of clinical features with laboratory findings in lupus erythematosus. Arch Dermatol. 1975 Nov. 111(11):1448-52. [View Abstract]
  5. Arkin LM, Ansell L, Rademaker A, et al. The natural history of pediatric-onset discoid lupus erythematosus. J Am Acad Dermatol. 2015 Apr. 72 (4):628-33. [View Abstract]
  6. Hawat T, Ballouz S, Megarbane H, Haber R. Pediatric discoid lupus erythematosus: Short report. Dermatol Ther. 2022 Jan. 35 (1):e15170. [View Abstract]
  7. Elman SA, Joyce C, Costenbader KH, Merola JF. Time to progression from discoid lupus erythematosus to systemic lupus erythematosus: a retrospective cohort study. Clin Exp Dermatol. 2020 Jan. 45 (1):89-91. [View Abstract]
  8. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 Aug. 64 (8):2677-86. [View Abstract]
  9. Vale ECSD, Garcia LC. Cutaneous lupus erythematosus: a review of etiopathogenic, clinical, diagnostic and therapeutic aspects. An Bras Dermatol. 2023 May-Jun. 98 (3):355-72. [View Abstract]
  10. Kahn JS, Deverapalli SC, Rosmarin DM. JAK-STAT signaling pathway inhibition: a role for treatment of discoid lupus erythematosus and dermatomyositis. Int J Dermatol. 2018 Aug. 57 (8):1007-1014. [View Abstract]
  11. Solé C, Gimenez-Barcons M, Ferrer B, Ordi-Ros J, Cortés-Hernández J. Microarray study reveals a transforming growth factor-β-dependent mechanism of fibrosis in discoid lupus erythematosus. Br J Dermatol. 2016 Aug. 175 (2):302-13. [View Abstract]
  12. Solé C, Domingo S, Ferrer B, Moliné T, Ordi-Ros J, Cortés-Hernández J. MicroRNA Expression Profiling Identifies miR-31 and miR-485-3p as Regulators in the Pathogenesis of Discoid Cutaneous Lupus. J Invest Dermatol. 2019 Jan. 139 (1):51-61. [View Abstract]
  13. Tian J, Zhang D, Yao X, Huang Y, Lu Q. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2023 Mar. 82 (3):351-6. [View Abstract]
  14. Jarukitsopa S, Hoganson DD, Crowson CS, Sokumbi O, Davis MD, Michet CJ Jr, et al. Epidemiology of systemic lupus erythematosus and cutaneous lupus erythematosus in a predominantly white population in the United States. Arthritis Care Res (Hoboken). 2015 May. 67 (6):817-28. [View Abstract]
  15. Drenkard C, Parker S, Aspey LD, Gordon C, Helmick CG, Bao G, et al. Racial Disparities in the Incidence of Primary Chronic Cutaneous Lupus Erythematosus in the Southeastern US: The Georgia Lupus Registry. Arthritis Care Res (Hoboken). 2019 Jan. 71 (1):95-103. [View Abstract]
  16. Izmirly P, Buyon J, Belmont HM, Sahl S, Wan I, Salmon J, et al. Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program. Lupus Sci Med. 2019. 6 (1):e000344. [View Abstract]
  17. Klein R, Moghadam-Kia S, Taylor L, Coley C, Okawa J, LoMonico J, et al. Quality of life in cutaneous lupus erythematosus. J Am Acad Dermatol. 2011 May. 64 (5):849-58. [View Abstract]
  18. Achtman J, Kling MA, Feng R, Okawa J, Werth VP. A cross-sectional study of untreated depression and anxiety in cutaneous lupus erythematosus and dermatomyositis. J Am Acad Dermatol. 2016 Feb. 74 (2):377-9. [View Abstract]
  19. Gordon H, Chandran A, Vandal AC, Yung A, Jarrett P. The relationship between disease severity and quality of life in discoid lupus erythematosus. Br J Dermatol. 2017 Oct. 177 (4):1134-1135. [View Abstract]
  20. Tao J, Zhang X, Guo N, et al. Squamous cell carcinoma complicating discoid lupus erythematosus in Chinese patients: review of the literature, 1964-2010. J Am Acad Dermatol. 2012 Apr. 66(4):695-6. [View Abstract]
  21. Zaalberg A, Moradi Tuchayi S, Ameri AH, Ngo KH, Cunningham TJ, Eliane JP, et al. Chronic inflammation promotes skin carcinogenesis in cancer-prone discoid lupus erythematosus. J Invest Dermatol. 2018 Jul 17. [View Abstract]
  22. Merola JF, Prystowsky SD, Iversen C, Gomez-Puerta JA, Norton T, Tsao P, et al. Association of discoid lupus erythematosus with other clinical manifestations among patients with systemic lupus erythematosus. J Am Acad Dermatol. 2013 Jul. 69 (1):19-24. [View Abstract]
  23. Parish LC, Kennedy RJ, Hurley J. Palmar lesions in lupus erythematosus. Arch Dermatol. 1967 Sep. 96(3):273-6. [View Abstract]
  24. McDaniel B, Sukumaran S, Koritala T, Tanner LS. Discoid Lupus Erythematosus. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2025 Jan.
  25. Rangel LK, Villa-Ruiz C, Lo K, et al. Clinical Characteristics of Lupus Erythematosus Panniculitis/Profundus: A Retrospective Review of 61 Patients. JAMA Dermatol. 2020 Nov 1. 156 (11):1264-6. [View Abstract]
  26. Elman SA, Joyce C, Nyberg F, Furukawa F, Goodfield M, Hasegawa M, et al. Development of classification criteria for discoid lupus erythematosus: Results of a Delphi exercise. J Am Acad Dermatol. 2017 Aug. 77 (2):261-267. [View Abstract]
  27. Biazar C, Sigges J, Patsinakidis N, Ruland V, Amler S, Bonsmann G, et al. Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev. 2013 Jan. 12 (3):444-54. [View Abstract]
  28. Kim A, O'Brien J, Tseng LC, Zhang S, Chong BF. Autoantibodies and disease activity in patients with discoid lupus erythematosus. JAMA Dermatol. 2014 Jun. 150 (6):651-4. [View Abstract]
  29. [Guideline] Kuhn A, Aberer E, Bata-Csörgő Z, et al. S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2017 Mar. 31 (3):389-404. [View Abstract]
  30. Jung H, Bobba R, Su J, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. 2010 Mar. 62(3):863-8. [View Abstract]
  31. Petri M. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep. 2011 Feb. 13(1):77-80. [View Abstract]
  32. Hannon CW, McCourt C, Lima HC, Chen S, Bennett C. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev. 2021 Mar 9. 3 (3):CD007478. [View Abstract]
  33. Callen JP, Spencer LV, Burruss JB, Holtman J. Azathioprine. An effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol. 1991 Apr. 127(4):515-22. [View Abstract]
  34. Nahmias Z, Nambudiri VE, Vleugels RA. Thalidomide and lenalidomide for the treatment of refractory dermatologic conditions. J Am Acad Dermatol. 2016 Jul. 75 (1):210-2. [View Abstract]
  35. Shah A, Albrecht J, Bonilla-Martinez Z, et al. Lenalidomide for the treatment of resistant discoid lupus erythematosus. Arch Dermatol. 2009 Mar. 145(3):303-6. [View Abstract]
  36. Callen JP. Cutaneous lupus erythematosus: a personal approach to management. Australas J Dermatol. 2006 Feb. 47(1):13-27. [View Abstract]
  37. Wahie S, Daly AK, Cordell HJ, et al. Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study. J Invest Dermatol. 2011 Oct. 131(10):1981-6. [View Abstract]
  38. [Guideline] Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF, American Academy of Ophthalmology. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016 Jun. 123 (6):1386-94. [View Abstract]
  39. Chang AY, Werth VP. Treatment of cutaneous lupus. Curr Rheumatol Rep. 2011 Aug. 13 (4):300-7. [View Abstract]
  40. Mittal L, Zhang L, Feng R, Werth VP. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study. J Am Acad Dermatol. 2018 Jan. 78 (1):100-106.e1. [View Abstract]
  41. Alves P, Bashir MM, Wysocka M, Zeidi M, Feng R, Werth VP. Quinacrine Suppresses Tumor Necrosis Factor-α and IFN-α in Dermatomyositis and Cutaneous Lupus Erythematosus. J Investig Dermatol Symp Proc. 2017 Oct. 18 (2):S57-S63. [View Abstract]
  42. Wahie S, Daly AK, Cordell HJ, et al. Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study. J Invest Dermatol. 2011 Oct. 131(10):1981-6. [View Abstract]
  43. Chasset F, Francès C, Barete S, Amoura Z, Arnaud L. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. J Am Acad Dermatol. 2015 Apr. 72 (4):634-9. [View Abstract]
  44. Kuhn A, Sigges J, Biazar C, et al. Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database. Br J Dermatol. 2014 Sep. 171 (3):571-9. [View Abstract]
  45. Piette EW, Foering KP, Chang AY, et al. Impact of smoking in cutaneous lupus erythematosus. Arch Dermatol. 2012 Mar. 148(3):317-22. [View Abstract]
  46. Spinelli FR, Moscarelli E, Ceccarelli F, Miranda F, Perricone C, Truglia S, et al. Treating lupus patients with antimalarials: analysis of safety profile in a single-center cohort. Lupus. 2018 Sep. 27 (10):1616-1623. [View Abstract]
  47. Gammon B, Hansen C, Costner MI. Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus. J Am Acad Dermatol. 2011 Oct. 65(4):717-21. [View Abstract]
  48. Kreuter A, Tomi NS, Weiner SM, Huger M, Altmeyer P, Gambichler T. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Br J Dermatol. 2007 Jun. 156(6):1321-7. [View Abstract]
  49. Kindle SA, Wetter DA, Davis MD, Pittelkow MR, Sciallis GF. Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience. Int J Dermatol. 2016 Aug. 55 (8):e431-9. [View Abstract]
  50. Okon L, Rosenbach M, Krathen M, Rose M, Propert K, Okawa J, et al. Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial. J Am Acad Dermatol. 2014 Mar. 70 (3):583-4. [View Abstract]
  51. Rosmarin D. Open label phase 2 pilot trial of oral tofactinib in adult subjects with discoid lupus erythematosus (DLE) and systemic lupus erythematosus (SLE). Report No.: NCT03159936. 2017.
  52. De Souza A, Strober BE, Merola JF, Oliver S, Franks AG Jr. Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study. J Drugs Dermatol. 2012 Oct. 11 (10):1224-6. [View Abstract]
  53. Tenti S, Fabbroni M, Mancini V, Russo F, Galeazzi M, Fioravanti A. Intravenous Immunoglobulins as a new opportunity to treat discoid lupus erythematosus: A case report and review of the literature. Autoimmun Rev. 2018 Aug. 17 (8):791-795. [View Abstract]
  54. Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012 Nov. 71 (11):1833-8. [View Abstract]
  55. Kuhn A, Landmann A, Wenzel J. Advances in the treatment of cutaneous lupus erythematosus. Lupus. 2016 Jul. 25 (8):830-7. [View Abstract]
  56. Herold M, Richmond NA, Montuno MA, Wesson SK, Motaparthi K. Rapamycin for refractory discoid lupus erythematosus. Dermatol Ther. 2018 Sep. 31 (5):e12631. [View Abstract]
  57. Shaw K, Sanchez-Melendez S, Taylor D, et al. Assessment of Clinical Response to Anifrolumab in Patients With Refractory Discoid Lupus Erythematosus. JAMA Dermatol. 2023 May 1. 159 (5):560-3. [View Abstract]
  58. Morand EF, Furie R, Tanaka Y, et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N Engl J Med. 2020 Jan 16. 382 (3):211-21. [View Abstract]
  59. Bao A, Petri MA, Fava A, Kang J. Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE. Lupus Sci Med. 2023 Dec 19. 10 (2):[View Abstract]
  60. Shaw K, Taylor D, Sanchez-Melendez S, et al. Improvement in mucosal discoid lupus erythematosus with anifrolumab. Clin Exp Dermatol. 2023 Sep 19. 48 (10):1165-7. [View Abstract]
  61. Shaw KS, Rajeh A, Le T, et al. Anifrolumab for Adolescent Discoid Lupus Erythematosus. JAMA Netw Open. 2023 Oct 2. 6 (10):e2338200. [View Abstract]
  62. Azuma N, Natsuaki M, Hashimoto N, et al. Efficacy of anifrolumab in long-term intractable alopecia due to discoid lupus erythematosus. Mod Rheumatol Case Rep. 2024 Jul 8. 8 (2):267-71. [View Abstract]
  63. Ocon A, Avalos Sugastti E, Duffy N. Impressive resolution of refractory hypertrophic discoid lupus erythematosus with anifrolumab. BMJ Case Rep. 2024 Jun 18. 17 (6):[View Abstract]
  64. Rerknimitr P, Tekacharin N, Panchaprateep R, Wititsuwannakul J, Tangtanatakul P, Hirankarn N, et al. Pulsed-dye laser as an adjuvant treatment for discoid lupus erythematosus: a randomized, controlled trial. J Dermatolog Treat. 2019 Feb. 30 (1):81-86. [View Abstract]
  65. Erceg A, Bovenschen HJ, van de Kerkhof PC, de Jong EM, Seyger MM. Efficacy and safety of pulsed dye laser treatment for cutaneous discoid lupus erythematosus. J Am Acad Dermatol. 2009 Apr. 60(4):626-32. [View Abstract]
  66. Callen JP. Management of "refractory" skin disease in patients with lupus erythematosus. Best Pract Res Clin Rheumatol. 2005 Oct. 19(5):767-84. [View Abstract]
  67. Yuki EFN, Silva CA, Aikawa NE, et al. Thalidomide and Lenalidomide for Refractory Systemic/Cutaneous Lupus Erythematosus Treatment: A Narrative Review of Literature for Clinical Practice. J Clin Rheumatol. 2021 Sep 1. 27 (6):248-59. [View Abstract]
  68. Housman TS, Jorizzo JL, McCarty MA, Grummer SE, Fleischer AB Jr, Sutej PG. Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus. Arch Dermatol. 2003 Jan. 139(1):50-4. [View Abstract]
  69. Chu S, Michelle L, Ekelem C, Sung CT, Rojek N, Mesinkovska NA. Oral isotretinoin for the treatment of dermatologic conditions other than acne: a systematic review and discussion of future directions. Arch Dermatol Res. 2021 Aug. 313 (6):391-430. [View Abstract]
  70. Tsianakas A, Herzog S, Landmann A, Patsinakidis N, Perusquía Ortiz AM, Bonsmann G, et al. Successful treatment of discoid lupus erythematosus with fumaric acid esters. J Am Acad Dermatol. 2014 Jul. 71(1):e15-7. [View Abstract]
  71. Debu A, Girard C, Bessis D. Discoid lupus erythematosus successfully treated by photodynamic therapy. Br J Dermatol. 2015 Mar. 172 (3):821-2. [View Abstract]
  72. Turan E, Sinem Bagci I, Turgut Erdemir A, Salih Gurel M. Successful treatment of generalized discoid lupus erythematosus with imiquimod cream 5%: a case report and review of the literature. Acta Dermatovenerol Croat. 2014. 22(2):150-9. [View Abstract]

Discoid lupus erythematosus on the face.

Chronic scarred lesion of discoid lupus erythematosus.

Discoid lupus erythematosus on the face.

Chronic scarred lesion of discoid lupus erythematosus.

Lesions of discoid lupus erythematosus in the conchal bowl demonstrate patulous follicles with follicular plugging.

Scarring alopecia of discoid lupus erythematosus.

Widespread scarring alopecia.

Palmar lesions of discoid lupus erythematosus.

Hypertrophic lesions of chronic cutaneous lupus erythematosus on the dorsal hands. Characteristic lesions were observed elsewhere.

Discoid lupus erythematosus on the face.

Chronic scarred lesion of discoid lupus erythematosus.

Lesions of discoid lupus erythematosus in the conchal bowl demonstrate patulous follicles with follicular plugging.

Palmar lesions of discoid lupus erythematosus.

Scarring alopecia of discoid lupus erythematosus.

Widespread scarring alopecia.

Hypertrophic lesions of chronic cutaneous lupus erythematosus on the dorsal hands. Characteristic lesions were observed elsewhere.